Last reviewed · How we verify

Peri

Ospedale San Raffaele · FDA-approved active Small molecule ✓ Verified May 2026 Quality 2/100

Peri is a Small molecule drug developed by Ospedale San Raffaele. It is currently FDA-approved. Also known as: Perindopril.

Peri is a supernatural entity originating from Persian tales and distributed into wider Asian folklore, often described as a winged creature of immense beauty. It has no relation to the substance studied in clinical trials, which is a small molecule inhibitor of the cell membrane.

At a glance

Generic namePeri
Also known asPerindopril
SponsorOspedale San Raffaele
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Peri

What is Peri?

Peri is a Small molecule drug developed by Ospedale San Raffaele.

Who makes Peri?

Peri is developed and marketed by Ospedale San Raffaele (see full Ospedale San Raffaele pipeline at /company/ospedale-san-raffaele).

Is Peri also known as anything else?

Peri is also known as Perindopril.

What development phase is Peri in?

Peri is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing